© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Dermatology in Primary Care: Evidence for the Total Body Skin Exam and Cautions on Cryotherapy
April 03, 2025
ACP 2025. A quick look at 2 topics in dermatology rounded out a Multiple Small Feedings of the Mind session at the 2025 American College of Physicians annual meeting.
Prostate Cancer Screening: Balancing Benefits and Harms in an Evolving Landscape
April 03, 2025
ACP 2025. Ruth Etzioni, PhD, discussed evidence-based approaches to screening for patients at average risk, start and stop criteria, MRI for follow-up screening, and other topics.
Research That Is Changing Endocrinology: Advances, Challenges, and The Future, with Irl B Hirsch, MD
April 03, 2025
ACP 2025: Irl B Hirsch, MD, reviewed findings from 8 papers published in 2024 that he believes have made or will make a difference in the practice or understanding of the clinical area.
Continuous Glucose Monitoring vs HbA1c: A Deep Dive into CGM Data and How to Use It
April 03, 2025
ACP 2025. Thomas Martens, MD, Gregg Simonson, PhD, and Libby Johnson, RDN, LD, CDCES explained the benefits of CGM, how to interpret data, and then adjust treatment accordingly.
Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo
April 01, 2025
Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.
Methylone (TSND-201) for PTSD Shows Rapid, Sustained Symptom Improvement in Phase 2 IMPACT-1 Trial
April 01, 2025
In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.
Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout
March 31, 2025
ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.
Lepodisiran Reduced Lp(a) Levels by Nearly 94% in Phase 2 ALPACA Trial, Slated for Phase 3 Development
March 31, 2025
Lepodisiran at 400 mg maintained reductions of Lp(a), an inherited risk factor for cardiovascular disease, at ~90% at 1 year and ~75% at 1.5 years, Eli Lilly reported.
Dupilumab is Safe and Effective Across Pediatric Populations with Severe Atopic Dermatitis: New Meta-Analysis
March 31, 2025
Dupilumab significantly improved measures of severe AD, including EASI and IGA, as well as pruritis in pediatric populations aged 6 months to 18 years vs placebo.
Pediatric Fentanyl Poisonings Spiral Up 1,200% Over 8 Years, Study Finds
March 28, 2025
In the pediatric population aged 0 to 19 years, exposure to fentanyl was through intentional use by two-thirds, investigators found.